Biolife Solutions Cm is now down by 6.99% percent from yesterday’s close losing $0.43. So far 125 shares have changed hands.
Biolife Solutions Cm news headlines.
BioLife Solutions Receives $1.9 Million from Exercise of Warrants
BioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials of Treg Cell Therapies
BioLife Solutions to Report Third Quarter 2017 Financial Results and Provide Business Update on November 9, 2017
BioLife Solutions Announces Third Quarter 2017 Financial Results.
Short traders are feeling a little more bullish on shares of the company recently if you consider the fall in short interest. The firm had a fall in short interest of -4.47% as of October 13, 2017 from the last reporting period. Short shares fell from 601,356 to 574,457 over that period. Days to cover increased 2.0 to 4.0 and the percentage of shorted shares is 0.04% as of October 13.
Here are a few substantial investment firms who have updated their positions. Deutsche Bank Ag augmented its investment by buying 72,300 shares an increase of 7,230,000.0% in the quarter. Deutsche Bank Ag now holds 72,301 shares worth $412,000. The total value of its holdings increased inf%. Schonfeld Strategic Advisors LLC grew its position by buying 190,000 shares an increase of 190.0%. Schonfeld Strategic Advisors LLC now controls 290,000 shares valued at $1,656,000. The value of the position overall is up by 592.9%.
Blackrock Inc. expanded its holdings by buying 399 shares an increase of 11.2% as of 09/30/2017. Blackrock Inc. controls 3,957 shares with a value of $23,000. The value of the position overall is up by 155.6%. Perkins Capital Management Inc bolstered its ownership by buying 5,000 shares an increase of 50.0% from 06/30/2017 to 09/30/2017. Perkins Capital Management Inc currently owns 15,000 shares valued at $86,000. The value of the position overall is up by 258.3%.
Equity analyst Maxim Group raised the price target of the stock on November 10 changing the price objective from $7.00 to $8.00 and stated a “Buy” rating. On October 26 Maxim Group maintained a company rating of “Buy” targeting a price of $7.00.
On October 19, 2017 Maxim Group released research on BLFS stating a rating of “Buy” and a price target of $7.00. Maxim Group raised the price target on September 19 changing the forecast from $6.00 to $7.00 and issued a “Buy” rating.
Equity analyst Maxim Group updated guidance on BLFS with a rating of “Buy” and price target of $6.00.
The most current P/E ratio is N/A and the market cap of the company is 77.97M. As of the last earnings report the EPS was $-0.42 with 13.63M shares outstanding.
BioLife Solutions, Inc. (BioLife), launched on March 25, 1998, is involved in developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage, and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Business’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products..